Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp vs Observation in High-risk Uveal Melanoma (ATOM)
NCT06246149Phase 3Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2024
- Primary completion
- Nov 2032
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 9
01
Overview
A Phase 3 trial of tebentafusp in Uveal melanoma (UM), sponsored by European Organisation for Research and Treatment of Cancer. Started Nov 2024; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06246149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06246149.